Dexmedetomidine is a highly specific Ci2adrenergic agonist, which is used clinically as an anesthetic adjuvant and in animal experiments has a neuroprotective ef fect during ischemia. The current study showed that dexme detomidine enhances glutamine disposal by oxidative metabo lism in astrocytes. This effect occurs at pharmacologically rel-Dexmedetomidine is a potent and highly specific (X2-
adrenergic agonist (Virtanen, 1989) used clinically as an anesthetic adjuvant (Aantaa et aI., 1997 , Venn et aI., 1999 . Doses of 1-100 fLg/kg have a neuroprotective effect during ischemia (Hoffman et aI., 1991; Maier et aI., 1993; Kuhmonen et aI., 1997; Jolkkonen et aI., 1999) . With a molecular weight of 186 and a volume of distri bution of 2-3 liter/kg (Scheinin et aI., 1992; Muge et aI., 1996) , the dose range corresponds to plasma concentra tions of 2.5-250 nmol/L.
It was originally assumed that all (X2-adrenergic recep tors are presynaptic and inhibit noradrenaline release.
Although (X2-adrenergic agonists have such an effect (Hong et aI., 1992; Matsumoto et aI., 1993; Gobert et aI., 1998) , compelling evidence for an additional localization on post-junctional target cells has appeared. The target cells include astrocytes (Ebersolt et aI., 1981; Lee et aI., 1998a,b) . Stimulation of astrocytic (X2-adrenergic re ceptors activates the phoshatidylinositol second mes senger system (Enkvist et aI., 1996) Chen and Hertz, 1999) . Clonidine, a less selective (X2-adrenergic agonist, also increases glutamine uptake in astrocytes and its subsequent oxidative degradation Hertz, 1994, 1995) .
The importance of glutamine for glutamate-induced excitotoxic injury is illustrated by the observation that a decrease of the glutamine concentration in the culturing medium reduces anoxic death of cultured neurons (Gold berg et aI., 1988; Huang et ai. 1997) . Oxidative degra dation of glutamine occurs through pyruvate and lactate (Sonnewald et aI., 1995; Schousboe et aI., 1994) . This is probably the main mechanism by which the brain dis poses of excess glutamine and glutamate (Hertz et aI., 1999 (Hertz et aI., , 2000 . During anoxia this process is halted, but it can be re-established after reoxygenation (Pascual et aI., 1998 ). In the current study it is shown that dexmedeto midine at pharmacologically relevant concentrations in creases glutamine oxidation in astrocytes. Cultures of astrocytes were prepared as previously described (Juurlink and Hertz, 1992; Hertz et aI., 1998) . The neopallia, that is, the parts of the cerebral hemispheres above the lateral ventricles, were dissected out of brains from newborn Swiss mice and mechanically dissociated in a slightly modified Dul becco's tissue culture medium (Juurlink and Hertz, 1992) . The cell suspension was seeded in Falcon Primaria culture dishes and grown under a CO2/air (5%/95%) atmosphere at 3rc. After 2 weeks the culturing was continued in the additional presence of 0.25 mmollL dibutyryl cyclic adenosine mono phosphate, which promotes morphologic and functional differ entiation (Meier et aI., 1991; Enkvist et aI., 1996) . The cultures were used after 3 to 6 weeks. (6) 25/-LmollL 125.0 ± 6. 0 (12)t 97. 8 ± 7. 4 (7) 115.0 ± 8.2 (7) Rates during exposure to 70 nmollL and 25 /-LmollL dexmedetomi dine and to 25 /-LmollL dexmedetomidine in the additional presence of yohimbine or idazoxan.
MATERIALS AND METHODS
* All values are expressed as percentages of the control value in the same experiment in the absence of any drug. Values are averages ± SEM with number of individual experiments shown in parentheses.
t The effect of 25 /-LffiollL dexmedetomidine is statistically signifi cantly different from both the control value and the value in the addi tional presence of yohimbine in ANOV A plus Fisher PLSD test for multiple comparisons.
:j: 100 /-LmollL.
underestimate because extracellular, not intracellular, specific activity was used for the determination (Zielke et ai., 1996) . However, because of possible intracellular compartmentation of glutamine (Schousboe et ai., 1994) , no attempt was made to correct this source of error.
The dexmedetomidine-induced stimulation of U-e4C]glutamine oxidation was exerted on 0'2adrenergic receptors as shown by its inhibition by yo himbine, an 0'2 antagonist (Table I) , but not by idazoxan, an inhibitor of the imidazoline binding site (Bylund, 1995) . The small, insignificant reduction of dexmedeto midine-stimulated 14C02 by idazoxan reflects that idazoxan, on its own, caused approximately a 10% re duction in the rate of 14C02 formation.
DISCUSSION
Dexmedetomidine in vivo exerts other actions than inhibiting noradrenaline release as proven by the fact it has a sedative effect and potentiates anesthetics in ani mals depleted for noradrenaline (Segal et aI., 1988; Riek kinen et aI., 1993) , an effect exerted within the central nervous system (Doze et ai., 1989) . The current results suggest that some of dexmedetomidine's actions are ex erted on astrocytic 0'2-adrenergic receptors. This is con sistent with a dexmedetomidine-induced increase in as trocytic [Ca 2 +l (Zhao et aI., 1992; Enkvist et aI., 1996; Chen et aI., 2000) .
In heart cells, an increase in [Ca 2 +]j resulting from adrenergic stimulation leads to uptake of K+ in mito chondria and swelling of the mitochondrial matrix, which in tum stimulates glutaminase activity (Halestrap, 1989) . The same mechanisms may operate in astrocytes because they display considerable glutaminase activity (Hogstad et aI., 1988; Aoki et aI., 1991; Wurdig and Kugler, 1991) , which is increased by clonidine Hertz, 1994, 1995) . Moreover, 0'2-adrenergic ago nists have a direct effect on oxidation of O'-ketoglutarate (Subbarao and Hertz, 1991) which, combined with an increased rate of formation of glutamate from glutamine, could explain the increase in glutamine oxidation seen in the current study.
Dexmedetomidine concentration of 70 nmollL, which stimulated glutamine oxidation by 25%, is within the plasma concentration range expected after administration of dexmedetomidine as a neuroprotectant. The effect is large enough that it may affect glutamine content in the brain, a novel mechanism of action for a neuroprotectant drug. Net synthesis of glutamate and glutamine from glucose depends upon pyruvate carboxylation, which in the brain occurs at a rate 10-15% of total TeA cycle activity (Lapidot and Gopher, 1994; Aureli et aI., 1997; Gruetter et aI., 1998) . Based upon this infonnation and a glucose utilization rate in the mouse brain of 60-70 f.Lmol/min per 100 g (Wree et aI., 1989) , it can be esti mated that the maximum rate of net glutamate/glutamine synthesis from glucose in the mouse brain amounts to 1.2-2.1 nmol/min-mg protein (Hertz et aI., 1999) . A dexmedetomidine-induced increase of glutamine dis posal of at least 0.2 nmol/min-mg protein may cause a substantial change in the balance between formation and disposal of glutamine, thus reducing the availability of glutamine as a glutamate precursor. This concept is con sistent with the observation by Talke and Bickler (1996) that glutamate release from hippocampal slices during hypoxia is decreased by dexmedetomidine.
